One meta-analysis showed that an increased risk of CTR-CVT was associated with early pre- and post-MPO assessment (HR 1.16, 90% CI 1.02–1.32) [75]; however, in addition to cardiac injury, the tumor itself may be responsible for elevated MPO levels after antineoplastic therapy, which partly contributes to the imprecision of MPO results. The gene discussed is MPO; the disease is neoplasm.